Bio-enhanced silk fibroin-based scaffolds for chronic diabetic foot ulcers

Abstract

Diabetic foot ulcers (DFUs) represent a growing clinical challenge, driven by an aging global population and the increasing prevalence of diabetes. Affecting millions worldwide, DFUs remain one of the most serious complications of diabetes, frequently progressing to infection, amputation, and elevated mortality. Standard treatments typically include pressure offloading, circulation improvement, infection control, and topical wound care; however, many chronic DFUs fail to respond to these interventions due to persistent inflammation, impaired vascularization, and microbial burden. These challenges have accelerated interest in regenerative medicine approaches, including stem cells, growth factors, and skin substitutes. Among these, skin substitutes have shown particular promise; among Food and Drug Administration-approved options, products such as the collagen-Manuka honey-hydroxyapatite patch from SweetBio (Apis^®) have demonstrated improved outcomes in patients with chronic ulcers. Silk fibroin (SF), a natural biopolymer with established clinical use, has emerged as a promising platform for chronic wound management due to its biocompatibility, tunable degradation, and capacity for controlled bio-additive delivery. SF scaffolds can be fabricated through various methods tailored to wound-healing applications: electrospun fibrous mats with high surface-area-to-volume ratio, freeze-dried porous constructs with interconnected architecture, and hydrogels designed for controlled drug delivery. In this review, we critically examine how SF scaffolds enhanced with bio-additives modulate cellular responses, redirect dysregulated healing pathways, accelerate wound closure, and promote tissue regeneration in diabetic wounds. We synthesize recent advances in preclinical and clinical studies, identify key translational barriers, and outline future directions for advancing SF-based dressings toward clinical adoption. Collectively, this review positions bio-enhanced SF scaffolds as next-generation, disease-informed candidates for improving outcomes in chronic DFU care.

Keywords

Diabetic foot ulcers / Chronic wound healing / Skin substitutes / Silk fibroin / Bio-additives / Scaffold fabrication / Growth factors / Tissue engineering / Regenerative medicine

References

[1] Pilla SJ, Rooney MR, McCoy RG. Disability and diabetes in adults. In Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT (eds). Diabetes in America. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2023. Accessed November 26, 2025. http://www.ncbi.nlm.nih.gov/books/NBK609951/.

[2] Idrees T, Castro-Revoredo I, Kantipudi S, Umpierrez G. Managing diabetes in older adults: current approaches in long-term care facilities. Curr Diab Rep. 2025; 25: 27. https://doi.org/10.1007/s11892-025-01583-5.

[3] Centers for Disease Control and Prevention . National Diabetes Statistics Report. Atlanta, GA: U.S. Department of Health and Human Services; 2024. Accessed November 24, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html.

[4] NCD Risk Factor Collaboration (NCD-RisC) . Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024; 404: 2077-93. https://doi.org/10.1016/S0140-6736(24)02317-1.

[5] GBD 2021 Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402: 203-34. https://doi.org/10.1016/S0140-6736(23)01301-6.

[6] Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107843. https://doi.org/10.1016/j.diabres.2019.107843.

[7] Packer CF, Ali SA, Manna B. Diabetic foot ulcer. In StatPearls. Treasure Island, FL: StatPearls Publishing, 2025. Accessed November 24, 2025. http://www.ncbi.nlm.nih.gov/books/NBK499887/.

[8] Jothivel N, Ponnusamy SP, Appachi M, Singaravel S, Rasilingam D, Deivasigamani K, et al. Anti-diabetic activity of methanol leaf extract of Costus pictus D. DON in Alloxan-induced diabetic rats. J Health Sci. 2007; 53: 655-63. https://doi.org/10.1248/jhs.53.655.

[9] Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers. JAMA. 2023; 330: 62-75. https://doi.org/10.1001/jama.2023.10578.

[10] Petersen BJ, Linde-Zwirble WT, Tan TW, Rothenberg GM, Salgado SJ, Bloom JD, et al. Higher rates of all-cause mortality and resource utilization during episodes-of-care for diabetic foot ulceration. Diabetes Res Clin Pract. 2022; 184: 109182. https://doi.org/10.1016/j.diabres.2021.109182.

[11] Ndosi M, Wright-Hughes A, Brown S, Backhouse M, Lipsky BA, Bhogal M, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med. 2018; 35: 78-88. https://doi.org/10.1111/dme.13537.

[12] Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007; 50: 18-25. https://doi.org/10.1007/s00125-006-0491-1.

[13] Skrepnek GH, Mills JL, Armstrong DG. A diabetic emergency one million feet Long: disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006-2010. PLoS One 2015; 10: e0134914. https://doi.org/10.1371/journal.pone.0134914.

[14] Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36: e3280. https://doi.org/10.1002/dmrr.3280.

[15] Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020; 13: 16. https://doi.org/10.1186/s13047-020-00383-2.

[16] Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons NB . Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014; 37: 651-8. https://doi.org/10.2337/dc13-2176.

[17] Baltzis D, Eleftheriadou I, Veves A. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014; 31: 817-36. https://doi.org/10.1007/s12325-014-0140-x.

[18] Holl J, Kowalewski C, Zimek Z, Fiedor P, Kaminski A, Oldak T, et al. Chronic diabetic wounds and their treatment with skin substitutes. Cells. 2021; 10: 655. https://doi.org/10.3390/cells10030655.

[19] Sood A, Granick MS, Tomaselli NL. Wound dressings and comparative effectiveness data. Adv Wound Care (New Rochelle). 2014; 3: 511-29. https://doi.org/10.1089/wound.2012.0401.

[20] Divyashri G, Badhe RV, Sadanandan B, Vijayalakshmi V, Kumari M, Ashrit P, et al. Applications of hydrogel-based delivery systems in wound care and treatment: an up-to-date review. Polym Adv Technol. 2022; 33: 2025-43. https://doi.org/10.1002/pat.5661.

[21] Güiza-Argüello VR, Solarte-David VA, Pinzón-Mora AV, Ávila-Quiroga JE, Becerra-Bayona SM. Current advances in the development of hydrogel-based wound dressings for diabetic foot ulcer treatment. Polymers. 2022; 14: 2764. https://doi.org/10.3390/polym14142764.

[22] Alven S, Peter S, Mbese Z, Aderibigbe BA . Polymer-based wound dressing materials loaded with bioactive agents: potential materials for the treatment of diabetic wounds. Polymers (Basel). 2022; 14: 724. https://doi.org/10.3390/polym14040724.

[23] Bardill JR, Laughter MR, Stager M, Liechty KW, Krebs MD, Zgheib C. Topical gel-based biomaterials for the treatment of diabetic foot ulcers. Acta Biomater. 2022; 138: 73-91. https://doi.org/10.1016/j.actbio.2021.10.045.

[24] Da Silva J, Leal EC, Carvalho E, Silva EA. Innovative functional biomaterials as therapeutic wound dressings for chronic diabetic foot ulcers. Int J Mol Sci. 2023; 24: 9900. https://doi.org/10.3390/ijms24129900.

[25] Vepari C, Kaplan DL. Silk as a biomaterial. Prog Polym Sci. 2007; 32: 991-1007. https://doi.org/10.1016/j.progpolymsci.2007.05.013.

[26] Aldahish A, Shanmugasundaram N, Vasudevan R, Alqhtani T, Alqahtani S, Mohammad Asiri A, et al. Silk fibroin nanofibers: advancements in bioactive dressings through electrospinning technology for diabetic wound healing. Pharmaceuticals (Basel). 2024; 17: 1305. https://doi.org/10.3390/ph17101305.

[27] Singh S, Young A, McNaught CE. The physiology of wound healing. Surgery (Oxford). 2017; 35: 473-7. https://doi.org/10.1016/j.mpsur.2017.06.004.

[28] Schilrreff P, Alexiev U. Chronic inflammation in non-healing skin wounds and promising natural bioactive compounds treatment. Int J Mol Sci. 2022; 23: 4928. https://doi.org/10.3390/ijms23094928.

[29] Percival SL, McCarty SM, Lipsky B. Biofilms and wounds: an overview of the evidence. Adv Wound Care (New Rochelle). 2015; 4: 373-81. https://doi.org/10.1089/wound.2014.0557.

[30] Lee J, Yun JS, Ko SH. Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus. Nutrients. 2022; 14: 3086. https://doi.org/10.3390/nu14153086.

[31] Mauricio D, Gratacòs M, Franch-Nadal J . Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves. Cardiovasc Diabetol. 2023; 22: 314. https://doi.org/10.1186/s12933-023-02056-3.

[32] Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. Transl Res. 2021; 236: 109-16. https://doi.org/10.1016/j.trsl.2021.05.006.

[33] Okonkwo UA, DiPietro LA. Diabetes and wound angiogenesis. Int J Mol Sci. 2017; 18: 1419. https://doi.org/10.3390/ijms18071419.

[34] Ueda N, Saito Y, Ota K, Nagao A, Kasseki D, Chikenji TS. The role of cellular senescence in wound healing of diabetic skin. J Biochem. 2026; 179: 241-8. https://doi.org/10.1093/jb/mvag006.

[35] Li H, Chen X, Ren K, Wu L, Chen G, Xu L. Qualitative study on diabetic cutaneous wound healing with radiation crosslinked bilayer collagen scaffold in rat model. Sci Rep. 2023; 13: 6399. https://doi.org/10.1038/s41598-023-33372-z.

[36] Hoversten KP, Kiemele LJ, Stolp AM, Takahashi PY, Verdoorn BP. Prevention, Diagnosis, and Management of Chronic Wounds in Older Adults. Mayo Clinic Proceedings. 2020; 95: 2021-34. https://doi.org/10.1016/j.mayocp.2019.10.014.

[37] Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017; 376: 2367-75. https://doi.org/10.1056/NEJMra1615439.

[38] Rodríguez I, Alvarez A, Massey C, Miller L, Rannou R, Croce M, et al. Novel bioengineered collagen with Manuka honey and hydroxyapatite sheet for the treatment of lower extremity chronic wounds in an urban hospital wound care setting. Wounds. 2023; 35: E35-8. https://doi.org/10.25270/wnds/22034.

[39] Veves A, Falanga V, Armstrong DG, Sabolinski ML, Apligraf Diabetic Foot Ulcer Study . Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24: 290-5. https://doi.org/10.2337/diacare.24.2.290.

[40] Landsman AS, Cook J, Cook E, Landsman AR, Garrett P, Yoon J, et al. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin^®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011; 4: 29-41. https://doi.org/10.1177/1938640010387417.

[41] Armstrong DG, Galiano RD, Orgill DP, Glat PM, Carter MJ, Di Domenico LA, et al. Multi-centre prospective randomised controlled clinical trial to evaluate a bioactive split thickness skin allograft vs standard of care in the treatment of diabetic foot ulcers. Int Wound J. 2022; 19: 932-44. https://doi.org/10.1111/iwj.13759.

[42] Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen. 1999; 7: 335-46. https://doi.org/10.1046/j.1524-475x.1999.00335.x.

[43] Zhao XH, Gu HF, Xu ZR, Zhang Q, Lv XY, Zheng XJ, et al. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: systematic review and meta-analysis. Metabolism. 2014; 63: 1304-13. https://doi.org/10.1016/j.metabol.2014.06.005.

[44] Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010; 33: 998-1003. https://doi.org/10.2337/dc09-1754.

[45] Perren S, Gatt A, Papanas N, Formosa C. Hyperbaric oxygen therapy in ischaemic foot ulcers in type 2 diabetes: a clinical trial. The Open Cardiovascular Medicine Journal. 2018; 12: 80-92. https://doi.org/10.2174/1874192401812010080.

[46] Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot wounds. Clin Infect Dis. 2006; 43: 188-92. https://doi.org/10.1086/505207.

[47] Bolton LL. Quality randomized clinical trials of topical diabetic foot ulcer healing agents. Adv Wound Care (New Rochelle). 2016; 5: 137-47. https://doi.org/10.1089/wound.2014.0571.

[48] Mazurek Ł, Szudzik M, Rybka M, Konop M. Silk fibroin biomaterials and their beneficial role in skin wound healing. Biomolecules. 2022; 12: 1852. https://doi.org/10.3390/biom12121852.

[49] Chouhan D, Janani G, Chakraborty B, Nandi SK, Mandal BB. Functionalized PVA-silk blended nanofibrous mats promote diabetic wound healing via regulation of extracellular matrix and tissue remodelling. J Tissue Eng Regen Med. 2018; 12: e1559-70. https://doi.org/10.1002/term.2581.

[50] Lin MJ, Lu MC, Chang HY. Sustained release of insulin-like growth factor-1 from Bombyx mori L. silk fibroin delivery for diabetic wound therapy. Int J Mol Sci. 2021; 22: 6267. https://doi.org/10.3390/ijms22126267.

[51] El Hage R, Knippschild U, Arnold T, Hinterseher I. Stem cell-based therapy: a promising treatment for diabetic foot ulcer. Biomedicines. 2022; 10: 1507. https://doi.org/10.3390/biomedicines10071507.

[52] Liu M, Wei X, Zheng Z, Li Y, Li M, Lin J, et al. Recent advances in nano-drug delivery Systems for the Treatment of diabetic wound healing. Int J Nanomedicine. 2023;Volume 18: 1537-60. https://doi.org/10.2147/IJN.S395438.

[53] Shi Y, Guo S, Tian J, Xie X, Shi J, Zhang X, et al. Biomaterials-mediated sequential drug delivery: emerging trends for wound healing. Asian J Pharm Sci 2025; 20: 101088. https://doi.org/10.1016/j.ajps.2025.101088.

[54] Islam MR, Manir MS, Razzak M, Mamun MA, Mortuza MF, Islam MJ, et al. Silk-enriched hydrogels with ROS-scavenging dendrimers for advanced wound care. Int J Biol Macromol. 2024; 280: 135567. https://doi.org/10.1016/j.ijbiomac.2024.135567.

[55] Zhang Q, Yan S, Li M. Silk fibroin based porous materials. Materials. 2009; 2: 2276-95. https://doi.org/10.3390/ma2042276.

[56] Nazarov R, Jin HJ, Kaplan DL. Porous 3-D scaffolds from regenerated silk fibroin. Biomacromolecules. 2004; 5: 718-26. https://doi.org/10.1021/bm034327e.

[57] Fang G, Sapru S, Behera S, Yao J, Shao Z, Kundu SC, et al. Exploration of the tight structural-mechanical relationship in mulberry and non-mulberry silkworm silks. J Mater Chem B. 2016; 4: 4337-47. https://doi.org/10.1039/c6tb01049k.

[58] Schmidt T, Puchalla N, Schendzielorz M, Kramell AE. Degumming and characterization of Bombyx mori and non-mulberry silks from Saturniidae silkworms. Sci Rep. 2023; 13: 19504. https://doi.org/10.1038/s41598-023-46474-5.

[59] Nguyen TP, Nguyen QV, Nguyen VH, Le TH, Huynh VQN, Vo DVN, et al. Silk fibroin-based biomaterials for biomedical applications: a review. Polymers (Basel). 2019; 11: 1933. https://doi.org/10.3390/polym11121933.

[60] Zhou CZ, Confalonieri F, Medina N, Zivanovic Y, Esnault C, Yang T, et al. Fine organization of Bombyx mori fibroin heavy chain gene. Nucleic Acids Res. 2000; 28: 2413-9. https://doi.org/10.1093/nar/28.12.2413.

[61] Tanaka K, Kajiyama N, Ishikura K, Waga S, Kikuchi A, Ohtomo K, et al. Determination of the site of disulfide linkage between heavy and light chains of silk fibroin produced by Bombyx mori. Biochim Biophys Acta Protein Struct Mol Enzymol. 1999; 1432: 92-103. https://doi.org/10.1016/S0167-4838(99)00088-6.

[62] Gage LP, Manning RF. Internal structure of the silk fibroin gene of Bombyx mori. I The fibroin gene consists of a homogeneous alternating array of repetitious crystalline and amorphous coding sequences. J Biol Chem. 1980; 255: 9444-50. https://doi.org/10.1016/S0021-9258(19)70582-1.

[63] Yamaguchi K, Kikuchi Y, Takagi T, Kikuchi A, Oyama F, Shimura K, et al. Primary structure of the silk fibroin light chain determined by cDNA sequencing and peptide analysis. J Mol Biol. 1989; 210: 127-39. https://doi.org/10.1016/0022-2836(89)90295-7.

[64] Zhou CZ, Confalonieri F, Jacquet M, Perasso R, Li ZG, Janin J. Silk fibroin: structural implications of a remarkable amino acid sequence. Proteins. 2001; 44: 119-22. https://doi.org/10.1002/prot.1078.

[65] Yankov G, Atanassova V, Karatodorov S, Stefanov R, Shumanov K, Iordanova E, et al. Investigation of the nonlinear optical properties of silk fibroin (SF) using the Z-scan method. Materials (Basel). 2025; 18: 1052. https://doi.org/10.3390/ma18051052.

[66] Ma L, Dong W, Lai E, Wang J. Silk fibroin-based scaffolds for tissue engineering. Front Bioeng Biotechnol. 2024; 12: 1381838. https://doi.org/10.3389/fbioe.2024.1381838.

[67] Zhao M, Qi Z, Tao X, Newkirk C, Hu X, Lu S. Chemical, thermal, time, and enzymatic stability of silk materials with silk I structure. Int J Mol Sci. 2021; 22: 4136. https://doi.org/10.3390/ijms22084136.

[68] Li AB, Kluge JA, Guziewicz NA, Omenetto FG, Kaplan DL. Silk-based stabilization of biomacromolecules. J Control Release. 2015; 219: 416-30. https://doi.org/10.1016/j.jconrel.2015.09.037.

[69] Qi Y, Wang H, Wei K, Yang Y, Zheng RY, Kim IS, et al. A review of structure construction of silk fibroin biomaterials from single structures to multi-level structures. Int J Mol Sci. 2017; 18: 237. https://doi.org/10.3390/ijms18030237.

[70] Tomeh MA, Hadianamrei R, Zhao X. Silk fibroin as a functional biomaterial for drug and gene delivery. Pharmaceutics. 2019; 11: 494. https://doi.org/10.3390/pharmaceutics11100494.

[71] Promsuk J, Manissorn J, Laomeephol C, Luckanagul JA, Methachittipan A, Tonsomboon K, et al. Optimizing protein delivery rate from silk fibroin hydrogel using silk fibroin-mimetic peptides conjugation. Sci Rep. 2024; 14: 4428. https://doi.org/10.1038/s41598-024-53689-7.

[72] Wani SUD, Zargar MI, Masoodi MH, Alshehri S, Alam P, Ghoneim MM, et al. Silk fibroin as an efficient biomaterial for drug delivery, gene therapy, and wound healing. Int J Mol Sci. 2022; 23: 14421. https://doi.org/10.3390/ijms232214421.

[73] Johari N, Moroni L, Samadikuchaksaraei A. Tuning the conformation and mechanical properties of silk fibroin hydrogels. Eur Polym J. 2020; 134: 109842. https://doi.org/10.1016/j.eurpolymj.2020.109842.

[74] Karve KA, Gil ES, McCarthy SP, Kaplan DL. Effect of β-sheet crystalline content on mass transfer in silk films. J Memb Sci. 2011; 383: 44-9. https://doi.org/10.1016/j.memsci.2011.08.032.

[75] Umuhoza D, Yang F, Long D, Hao Z, Dai J, Zhao A. Strategies for tuning the biodegradation of silk fibroin-based materials for tissue engineering applications. ACS Biomater Sci Eng. 2020; 6: 1290-310. https://doi.org/10.1021/acsbiomaterials.9b01781.

[76] Lehmann T, Vaughn AE, Seal S, Liechty KW, Zgheib C. Silk fibroin-based therapeutics for impaired wound healing. Pharmaceutics. 2022; 14: 651. https://doi.org/10.3390/pharmaceutics14030651.

[77] Deng X, Gould M, Ali MA. A review of current advancements for wound healing: biomaterial applications and medical devices. J Biomed Mater Res B Appl Biomater. 2022; 110: 2542-73. https://doi.org/10.1002/jbm.b.35086.

[78] Zhang X, Shu W, Yu Q, Qu W, Wang Y, Li R. Functional biomaterials for treatment of chronic wound. Front Bioeng Biotechnol. 2020; 8: 516. https://doi.org/10.3389/fbioe.2020.00516.

[79] Indrakumar S, Dash TK, Mishra V, Tandon B, Chatterjee K. Silk fibroin and its nanocomposites for wound care: a comprehensive review. ACS Polym Au. 2024; 4: 168-88. https://doi.org/10.1021/acspolymersau.3c00050.

[80] Thurber AE, Omenetto FG, Kaplan DL. In vivo bioresponses to silk proteins. Biomaterials. 2015; 71: 145-57. https://doi.org/10.1016/j.biomaterials.2015.08.039.

[81] Rockwood DN, Preda RC, Yücel T, Wang X, Lovett ML, Kaplan DL. Materials fabrication from Bombyx mori silk fibroin. Nat Protoc. 2011; 6: 1612-31. https://doi.org/10.1038/nprot.2011.379.

[82] Sashina ES, Bochek AM, Novoselov NP, Kirichenko DA. Structure and solubility of natural silk fibroin. Russ J Appl Chem. 2006; 79: 869-76. https://doi.org/10.1134/S1070427206060012.

[83] Lotfollahi Z. The anatomy, physiology and function of all skin layers and the impact of ageing on the skin. Wound Pract Res. 2024; 32: 6-10. https://doi.org/10.33235/wpr.32.1.6-10.

[84] Oltulu P, Ince B, Kokbudak N, Findik S, Kilinc F. Measurement of epidermis, dermis, and total skin thicknesses from six different body regions with a new ethical histometric technique. Turk J Plast Surg. 2018; 26: 56. https://doi.org/10.4103/tjps.TJPS_2_17.

[85] Xue J, Wu T, Dai Y, Xia Y. Electrospinning and electrospun nanofibers: methods, materials, and applications. Chem Rev 2019; 119: 5298-415. https://doi.org/10.1021/acs.chemrev.8b00593.

[86] Park YR, Ju HW, Lee JM, Kim DK, Lee OJ, Moon BM, et al. Three-dimensional electrospun silk-fibroin nanofiber for skin tissue engineering. Int J Biol Macromol. 2016; 93: 1567-74. https://doi.org/10.1016/j.ijbiomac.2016.07.047.

[87] Sheikh FA, Ju HW, Lee JM, Moon BM, Park HJ, Lee OJ, et al. 3D electrospun silk fibroin nanofibers for fabrication of artificial skin. Nanomedicine. 2015; 11: 681-91. https://doi.org/10.1016/j.nano.2014.11.007.

[88] Matthews JA, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen nanofibers. Biomacromolecules. 2002; 3: 232-8. https://doi.org/10.1021/bm015533u.

[89] Madappura AP, Madduri S. A comprehensive review of silk-fibroin hydrogels for cell and drug delivery applications in tissue engineering and regenerative medicine. Comput Struct Biotechnol J. 2023; 21: 4868-86. https://doi.org/10.1016/j.csbj.2023.10.012.

[90] Yin Z, Wu F, Xing T, Yadavalli VK, Kundu SC, Lu S. A silk fibroin hydrogel with reversible sol-gel transition. RSC Adv. 2017; 7: 24085-96. https://doi.org/10.1039/C7RA02682J.

[91] Cao H, Duan L, Zhang Y, Cao J, Zhang K. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther. 2021; 6: 426. https://doi.org/10.1038/s41392-021-00830-x.

[92] Bustamante-Torres M, Romero-Fierro D, Arcentales-Vera B, Palomino K, Magaña H, Bucio E. Hydrogels classification according to the physical or chemical interactions and as stimuli-sensitive materials. Gels. 2021; 7: 182. https://doi.org/10.3390/gels7040182.

[93] Roehm KD, Madihally SV. Bioprinted chitosan-gelatin thermosensitive hydrogels using an inexpensive 3D printer. Biofabrication. 2018; 10: 015002. https://doi.org/10.1088/1758-5090/aa96dd.

[94] Highley CB, Rodell CB, Burdick JA. Direct 3D printing of shear-thinning hydrogels into self-healing hydrogels. Adv Mater. 2015; 27: 5075-9. https://doi.org/10.1002/adma.201501234.

[95] Unagolla JM, Jayasuriya AC. Hydrogel-based 3D bioprinting: a comprehensive review on cell-laden hydrogels, bioink formulations, and future perspectives. Appl Mater Today. 2020; 18: 100479. https://doi.org/10.1016/j.apmt.2019.100479.

[96] Kapoor S, Kundu SC. Silk protein-based hydrogels: promising advanced materials for biomedical applications. Acta Biomater. 2016; 31: 17-32. https://doi.org/10.1016/j.actbio.2015.11.034.

[97] Zhou H, Wang Z, Cao H, Hu H, Luo Z, Yang X, et al. Genipin-crosslinked polyvinyl alcohol/silk fibroin/nano-hydroxyapatite hydrogel for fabrication of artificial cornea scaffolds-a novel approach to corneal tissue engineering. J Biomater Sci Polym Ed. 2019; 30: 1604-19. https://doi.org/10.1080/09205063.2019.1652418.

[98] Ferrero F, Periolatto M, Burelli S, Carletto RA. Silk grafting with chitosan and crosslinking agents. Fibers Polym. 2010; 11: 185-92. https://doi.org/10.1007/s12221-010-0185-7.

[99] Annabi N, Nichol JW, Zhong X, Ji C, Koshy S, Khademhosseini A, et al. Controlling the porosity and microarchitecture of hydrogels for tissue engineering. Tissue Eng Part B Rev. 2010; 16: 371-83. https://doi.org/10.1089/ten.teb.2009.0639.

[100] Naranjo-Alcazar R, Bendix S, Groth T, Gallego FG. Research progress in enzymatically cross-linked hydrogels as injectable systems for bioprinting and tissue engineering. Gels. 2023; 9: 230. https://doi.org/10.3390/gels9030230.

[101] Xu J, Liu X, Ren X, Gao G. The role of chemical and physical crosslinking in different deformation stages of hybrid hydrogels. Eur Polym J. 2018; 100: 86-95. https://doi.org/10.1016/j.eurpolymj.2018.01.020.

[102] Rebers L, Reichsöllner R, Regett S, Tovar GEM, Borchers K, Baudis S, et al. Differentiation of physical and chemical cross-linking in gelatin methacryloyl hydrogels. Sci Rep. 2021; 11: 3256. https://doi.org/10.1038/s41598-021-82393-z.

[103] Han H, Ning H, Liu S, Lu Q, Fan Z, Lu H, et al. Silk biomaterials with vascularization capacity. Adv Funct Mater. 2016; 26: 421-32. https://doi.org/10.1002/adfm.201504160.

[104] Rnjak-Kovacina J, Wray LS, Burke KA, Torregrosa T, Golinski JM, Huang W, et al. Lyophilized silk sponges: a versatile biomaterial platform for soft tissue engineering. ACS Biomater Sci Eng. 2015; 1: 260-70. https://doi.org/10.1021/ab500149p.

[105] Zhou C, Ma L, Li W, Yao D. Fabrication of tissue engineering scaffolds through solid-state foaming of immiscible polymer blends. Biofabrication. 2011; 3: 045003. https://doi.org/10.1088/1758-5082/3/4/045003.

[106] Mi HY, Jing X, Turng LS. Fabrication of porous synthetic polymer scaffolds for tissue engineering. J Cell Plast. 2015; 51: 165-96. https://doi.org/10.1177/0021955X14531002.

[107] Tai H, Mather ML, Howard D, Wang W, White LJ, Crowe JA, et al. Control of pore size and structure of tissue engineering scaffolds produced by supercritical fluid processing. Eur Cell Mater. 2007; 14: 64-77. https://doi.org/10.22203/ecm.v014a07.

[108] Chen RR, Mooney DJ. Polymeric growth factor delivery strategies for tissue engineering. Pharm Res. 2003; 20: 1103-12. https://doi.org/10.1023/a:1025034925152.

[109] Nurkesh A, Jaguparov A, Jimi S, Saparov A. Recent advances in the controlled release of growth factors and cytokines for improving cutaneous wound healing. Front Cell Dev Biol. 2020; 8: 1-7. https://doi.org/10.3389/fcell.2020.00638.

[110] Yucel T, Lovett ML, Kaplan DL. Silk-based biomaterials for sustained drug delivery. J Control Release. 2014; 190: 381-97. https://doi.org/10.1016/j.jconrel.2014.05.059.

[111] Sen S, Basak P, Prasad Sinha B, Maurye P, Kumar Jaiswal K, Das P, et al. Anti-inflammatory effect of epidermal growth factor conjugated silk fibroin immobilized polyurethane ameliorates diabetic burn wound healing. Int J Biol Macromol. 2020; 143: 1009-32. https://doi.org/10.1016/j.ijbiomac.2019.09.219.

[112] Darwitz BP, Genito CJ, Thurlow LR. Triple threat: how diabetes results in worsened bacterial infections. Infect Immun. 2024; 92: e0050923-3. https://doi.org/10.1128/iai.00509-23.

[113] Khan AUR, Huang K, Jinzhong Z, Zhu T, Morsi Y, Aldalbahi A, et al. Exploration of the antibacterial and wound healing potential of a PLGA/silk fibroin based electrospun membrane loaded with zinc oxide nanoparticles. J Mater Chem B. 2021; 9: 1452-65. https://doi.org/10.1039/D0TB02822C.

[114] Kandhasamy S, Liang B, Yang DP, Zeng Y. Antibacterial vitamin K3 carnosine peptide-laden silk fibroin electrospun fibers for improvement of skin wound healing in diabetic rats. ACS Appl Bio Mater. 2021; 4: 4769-88. https://doi.org/10.1021/acsabm.0c01650.

[115] Nanordica Medical OU . A Randomized, Double Blind, Active Controlled, Parallel Group Clinical Trial to Assess the Safety and Efficacy of Nanordica Antibacterial Wound Dressing in Patients With DFUs. clinicaltrials.gov Bethesda, MD: U.S. National Library of Medicine; 2025. Accessed March 5, 2026. https://clinicaltrials.gov/study/NCT06667752.

[116] First-in-class Wound Care Products. Tallinn, Estonia: Nanordica Medical OÜ. Accessed March 5, 2026. https://www.nanordica.com.

[117] Vasiliev G, Kubo AL, Bondarenko O, Valkna A. EP183 nanordica medical silk fibroin wound dressing with synergistic antibacterial effect showed better wound healing compared to popular product on the market. European Wound Management Association (EWMA) Conference, May 3-5, 2023, Milan, Italy. J Wound Manag. 2023; 24: 130-0.

[118] Wang R, Li B, Dong M, Zhu H, Jin P, Zou Y. Targeting oxidative damage in diabetic foot ulcers: integrative strategies involving antioxidant drugs and nanotechnologies. Burns Trauma. 2025; 13: tkaf020. https://doi.org/10.1093/burnst/tkaf020.

[119] Agarwal Y, Rajinikanth PS, Ranjan S, Tiwari U, Balasubramnaiam J, Pandey P, et al. Curcumin loaded polycaprolactone−/polyvinyl alcohol-silk fibroin based electrospun nanofibrous mat for rapid healing of diabetic wound: an in-vitro and in-vivo studies. Int J Biol Macromol. 2021; 176: 376-86. https://doi.org/10.1016/j.ijbiomac.2021.02.025.

[120] Venkatasubbu GD, Anusuya T. Investigation on curcumin nanocomposite for wound dressing. Int J Biol Macromol 2017; 98: 366-78. https://doi.org/10.1016/j.ijbiomac.2017.02.002.

[121] Liu J, Yan L, Yang W, Lan Y, Zhu Q, Xu H, et al. Controlled-release neurotensin-loaded silk fibroin dressings improve wound healing in diabetic rat model. Bioact Mater. 2019; 4: 151-9. https://doi.org/10.1016/j.bioactmat.2019.03.001.

[122] Brun P, Mastrotto C, Beggiao E, Stefani A, Barzon L, Sturniolo GC, et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G621-9. https://doi.org/10.1152/ajpgi.00140.2004.

[123] Moura JA, Barlow HJ, Doak SH, Hawkins K, Muller I, Clift MJD. Exploring the role of fibrin gels in enhancing cell migration for vasculature formation. J Funct Biomater. 2024; 15: 265. https://doi.org/10.3390/jfb15090265.

[124] Nie C, Yang D, Xu J, Si Z, Jin X, Zhang J. Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. Cell Transplant. 2011; 20: 205-16. https://doi.org/10.3727/096368910X520065.

[125] Cheng HW, Tsui YK, Cheung KMC, Chan D, Chan BP. Decellularization of chondrocyte-encapsulated collagen microspheres: a three-dimensional model to study the effects of acellular matrix on stem cell fate. Tissue Eng Part C Methods. 2009; 15: 697-706. https://doi.org/10.1089/ten.TEC.2008.0635.

[126] Chen RN, Ho HO, Tsai YT, Sheu MT. Process development of an acellular dermal matrix (ADM) for biomedical applications. Biomaterials. 2004; 25: 2679-86. https://doi.org/10.1016/j.biomaterials.2003.09.070.

[127] Hoshiba T, Lu H, Kawazoe N, Chen G. Decellularized matrices for tissue engineering. Expert Opin Biol Ther. 2010; 10: 1717-28. https://doi.org/10.1517/14712598.2010.534079.

[128] Navone SE, Pascucci L, Dossena M, Ferri A, Invernici G, Acerbi F, et al. Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. Stem Cell Res Ther 2014; 5: 7. https://doi.org/10.1186/scrt396.

[129] Bogadi S, Malayandi R, Vasanth Raj P, Kumar PS, Parvathaneni M, Kumar Kundu M, et al. Silk fibroin and sericin: multifunctional formulations for treating diabetic wound healing. Eur Polym J. 2024; 220: 113465. https://doi.org/10.1016/j.eurpolymj.2024.113465.

[130] Shitole M, Dugam S, Tade R, Nangare S. Pharmaceutical applications of silk sericin. Ann Pharm Fr. 2020; 78: 469-86. https://doi.org/10.1016/j.pharma.2020.06.005.

[131] Aramwit P, Kanokpanont S, Nakpheng T, Srichana T. The effect of sericin from various extraction methods on cell viability and collagen production. Int J Mol Sci. 2010; 11: 2200- 11. https://doi.org/10.3390/ijms11052200.

[132] Sun Y, Shi W, Zhang Q, Guo H, Dong Z, Zhao P, et al. Multi-omics integration to reveal the mechanism of sericin inhibiting LPS-induced inflammation. Int J Mol Sci. 2023; 24: 259. https://doi.org/10.3390/ijms24010259.

[133] Rahimpour S, Jabbari H, Yousofi H, Fathi A, Mahmoodi S, Jafarian MJ, et al. Regulatory effect of sericin protein in inflammatory pathways; a comprehensive review. Pathol Res Pract. 2023; 243: 154369. https://doi.org/10.1016/j.prp.2023.154369.

[134] Kanyora MG, Kegode TM, Kurgat J, Kibogo H, Asudi G, Tanga CM, et al. Evaluating antibacterial and antioxidant properties of sericin recovered from cocoons of Bombyx mori, Gonometa postica and Samia ricini in Kenya. PLoS One. 2024; 19: e0316259. https://doi.org/10.1371/journal.pone.0316259.

[135] Noda K, Kawai K, Matsuura Y, Ito-Ihara T, Amino Y, Ushimaru M, et al. Safety of silk-elastin sponges in patients with chronic skin ulcers: a phase I/II, single-center, open-label, single-arm clinical trial. Plast Reconstr Surg Glob Open. 2021; 9: e3556. https://doi.org/10.1097/GOX.0000000000003556.

[136] Yang H, Lai C, Xuan C, Chai M, Liu X, Chen Y, et al. Integrin-binding pro-survival peptide engineered silk fibroin nanosheets for diabetic wound healing and skin regeneration. Chem Eng J. 2020; 398: 125617. https://doi.org/10.1016/j.cej.2020.125617.

[137] Xu X, Wang X, Qin C, Khan AUR, Zhang W, Mo X. Silk fibroin/poly-(L-lactide-co-caprolactone) nanofiber scaffolds loaded with Huangbai liniment to accelerate diabetic wound healing. Colloids Surf B Biointerfaces. 2021; 199: 111557. https://doi.org/10.1016/j.colsurfb.2021.111557.

[138] Inpanya P, Faikrua A, Ounaroon A, Sittichokechaiwut A, Viyoch J. Effects of the blended fibroin/aloe gel film on wound healing in streptozotocin-induced diabetic rats. Biomed Mater. 2012; 7: 035008. https://doi.org/10.1088/1748-6041/7/3/035008.

[139] Kuwana Y, Sezutsu H, Nakajima K, Tamada Y, Kojima K. High-toughness silk produced by a transgenic silkworm expressing spider (Araneus ventricosus) dragline silk protein. PLoS One. 2014; 9: e105325. https://doi.org/10.1371/journal.pone.0105325.

[140] Bitar L, Isella B, Bertella F, Bettker Vasconcelos C, Harings J, Kopp A, et al. Sustainable Bombyx mori’s silk fibroin for biomedical applications as a molecular biotechnology challenge: a review. Int J Biol Macromol. 2024; 264: 130374. https://doi.org/10.1016/j.ijbiomac.2024.130374.

[141] Deptuch T, Dams-Kozlowska H. Silk materials functionalized via genetic engineering for biomedical applications. Materials (Basel). 2017; 10: 1417. https://doi.org/10.3390/ma10121417.

[142] Wohlrab S, Müller S, Schmidt A, Neubauer S, Kessler H, Leal-Egaña A, et al. Cell adhesion and proliferation on RGD-modified recombinant spider silk proteins. Biomaterials. 2012; 33: 6650-9. https://doi.org/10.1016/j.biomaterials.2012.05.069.

[143] Widhe M, Johansson U, Hillerdahl CO, Hedhammar M. Recombinant spider silk with cell binding motifs for specific adherence of cells. Biomaterials. 2013; 34: 8223- 34. https://doi.org/10.1016/j.biomaterials.2013.07.058.

[144] Saotome T, Hayashi H, Tanaka R, Kinugasa A, Uesugi S, Tatematsu K, et al. Introduction of VEGF or RGD sequences improves revascularization properties of Bombyx mori silk fibroin produced by transgenic silkworm. J Mater Chem B. 2015; 3: 7109-16. https://doi.org/10.1039/C5TB00939A.

[145] Ghalei S, Handa H. A review on antibacterial silk fibroin-based biomaterials: current state and prospects. Mater Today Chem. 2022; 23: 100673. https://doi.org/10.1016/j.mtchem.2021.100673.

[146] Pritchard EM, Valentin T, Panilaitis B, Omenetto F, Kaplan DL. Antibiotic-releasing silk biomaterials for infection prevention and treatment. Adv Funct Mater. 2013; 23: 854-61. https://doi.org/10.1002/adfm.201201636.

[147] Tang X, Tian C, Zhang X, Chen Y, Luo T, Zhao P, et al. Genetically engineered silk-based core-shell cytokine/sericin/carboxychitosan composite biomaterials for enhanced cell proliferation and medical applications. Int J Biol Macromol. 2026; 339: 149903. https://doi.org/10.1016/j.ijbiomac.2025.149903.

[148] Long D, Cheng X, Hao Z, Sun J, Umuhoza D, Liu Y, et al. Genetic hybridization of highly active exogenous functional proteins into silk-based materials using “light-clothing” strategy. Matter. 2021; 4: 2039-58. https://doi.org/10.1016/j.matt.2021.03.020.

[149] Teulé F, Miao YG, Sohn BH, Kim YS, Hull JJ, Fraser MJ. et al. Silkworms transformed with chimeric silkworm/spider silk genes spin composite silk fibers with improved mechanical properties. Proc Natl Acad Sci. 2012; 109: 923-8. https://doi.org/10.1073/pnas.1109420109.

[150] Yu Y, Chen K, Wang J, Zhang Z, Hu B, Liu X, et al. Custom-designed, mass silk production in genetically engineered silkworms. PNAS Nexus. 2024; 3: pgae128. https://doi.org/10.1093/pnasnexus/pgae128.

[151] Karthikeyan K, Sekar S, Devi MP, Inbasekaran S, Lakshminarasaiah CH, Sastry TP. Fabrication of novel biofibers by coating silk fibroin with chitosan impregnated with silver nanoparticles. J Mater Sci Mater Med. 2011; 22: 2721-6. https://doi.org/10.1007/s10856-011-4462-9.

[152] Liu Y, Zhou S, Gao Y, Zhai Y. Electrospun nanofibers as a wound dressing for treating diabetic foot ulcer. Asian J Pharm Sci. 2019; 14: 130-43. https://doi.org/10.1016/j.ajps.2018.04.004.

[153] Huang YY, Lin CW, Cheng NC, Cazzell SM, Chen HH, Huang KF, et al. Effect of a novel macrophage-regulating drug on wound healing in patients with diabetic foot ulcers: a randomized clinical trial. JAMA Netw Open. 2021; 4: e2122607. https://doi.org/10.1001/jamanetworkopen.2021.22607.

[154] Husain K, Malik A, Kirchens J, Choi G. A prospective, blinded, randomized controlled clinical trial evaluating the effect of the synthetic electrospun fiber matrix in the treatment of chronic diabetic foot ulcers. FASTRAC. 2024; 4: 100362. https://doi.org/10.1016/j.fastrc.2024.100362.

[155] Rai V, Moellmer R, Agrawal DK. Role of fibroblast plasticity and heterogeneity in modulating angiogenesis and healing in the diabetic foot ulcer. Mol Biol Rep. 2023; 50: 1913-29. https://doi.org/10.1007/s11033-022-08107-4.

[156] Kamalathevan P, Ooi PS, Loo YL. Silk-based biomaterials in cutaneous wound healing: a systematic review. Adv Skin Wound Care. 2018; 31: 565-73. https://doi.org/10.1097/01.ASW.0000546233.35130.a9.

[157] Lu G, Ding Z, Wei Y, Lu X, Lu Q, Kaplan DL. Anisotropic biomimetic silk scaffolds for improved cell migration and healing of skin wounds. ACS Appl Mater Interfaces. 2018; 10: 44314-23. https://doi.org/10.1021/acsami.8b18626.

[158] Park YR, Sultan MT, Park HJ, Lee JM, Ju HW, Lee OJ, et al. NF-κB signaling is key in the wound healing processes of silk fibroin. Acta Biomater. 2018; 67: 183-95. https://doi.org/10.1016/j.actbio.2017.12.006.

[159] Krizanova O, Penesova A, Sokol J, Hokynkova A, Samadian A, Babula P. Signaling pathways in cutaneous wound healing. Front Physiol. 2022; 13: 13. https://doi.org/10.3389/fphys.2022.1030851.

[160] Liu Z, Fang Y. Wound healing and signaling pathways. Open Life Sci. 2025; 20: 20251166. https://doi.org/10.1515/biol-2025-1166.

[161] Wray LS, Hu X, Gallego J, Georgakoudi I, Omenetto FG, Schmidt D, et al. Effect of processing on silk-based biomaterials: reproducibility and biocompatibility. J Biomed Mater Res B Appl Biomater. 2011; 99: 89-101. https://doi.org/10.1002/jbm.b.31875.

[162] Rnjak-Kovacina J, DesRochers TM, Burke KA, Kaplan DL. The effect of sterilization on silk fibroin biomaterial properties. Macromol Biosci 2015; 15: 861-74. https://doi.org/10.1002/mabi.201500013.

[163] Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023; 9: e17488. https://doi.org/10.1016/j.heliyon.2023.e17488.

[164] Lotfipour F, Shahi S, Farjami A, Salatin S, Mahmoudian M, Dizaj SM. Safety and toxicity issues of therapeutically used nanoparticles from the oral route. Biomed Res Int. 2021; 2021: 9322282. https://doi.org/10.1155/2021/9322282.

[165] Ma X, Tian Y, Yang R, Wang H, Allahou LW, Chang J, et al. Nanotechnology in healthcare, and its safety and environmental risks. J Nanobiotechnol. 2024; 22: 715. https://doi.org/10.1186/s12951-024-02901-x.

[166] Li M, Xia W, Khoong YM, Huang L, Huang X, Liang H, et al. Smart and versatile biomaterials for cutaneous wound healing. Biomater Res. 2023; 27: 87. https://doi.org/10.1186/s40824-023-00426-2.

[167] Chang SC, Lin CW, Chen JC, Wu YH, Chen SG, Huang YY, et al. Effects of ON101 for hard-to-heal diabetic foot ulcers in a randomized phase III trial: a post hoc analysis. Adv Wound Care (New Rochelle). 2025; 14: 381-92. https://doi.org/10.1089/wound.2023.0167.

[168] APIS^®. APIS^®. Accessed March 5, 2026. https://www.recoverwithapis.com.

[169] Du Y, Wang J, Fan W, Huang R, Wang H, Liu G. Preclinical study of diabetic foot ulcers: from pathogenesis to vivo/vitro models and clinical therapeutic transformation. Int Wound J. 2023; 20: 4394-409. https://doi.org/10.1111/iwj.14311.

[170] Rai V, Moellmer R, Agrawal DK. Clinically relevant experimental rodent models of diabetic foot ulcer. Mol Cell Biochem. 2022; 477: 1239-47. https://doi.org/10.1007/s11010-022-04372-w.

[171] Baptista-Silva S, Bernardes BG, Borges S, Rodrigues I, Fernandes R, Gomes-Guerreiro S, et al. Exploring silk Sericin for diabetic wounds: an in situ-forming hydrogel to protect against oxidative stress and improve tissue healing and regeneration. Biomolecules. 2022; 12: 801. https://doi.org/10.3390/biom12060801.

[172] Zhao X, Zhang Y, Huang Z, Wu X, Lin J. Innovative therapies for diabetic foot ulcers: application and prospects of smart dressings. Biomed Pharmacother. 2025; 191: 118498. https://doi.org/10.1016/j.biopha.2025.118498.

[173] Cheng X, Wang Y, Qian J, Bai R. Injectable silk fibroin hydrogel encapsulating pH-responsive ZnS nanoparticles for synergistic redox modulation and diabetic wound healing. Biomater Adv. 2026; 182: 214674. https://doi.org/10.1016/j.bioadv.2025.214674.

[174] Chan L, Lu Y, Taledaohan A, Wang Y, Wang W, Wang Y. A silk fibroin/chitosan hydrogel with ferulic acid derivatives: promoting diabetic wound healing through immune modulation and angiogenesis. Int J Biol Macromol. 2025; 322: 146744. https://doi.org/10.1016/j.ijbiomac.2025.146744.

[175] Wang Q, Liu C, An J, Liu J, Wang Y, Cai Y. Mechanisms of microbial infection and wound healing in diabetic foot ulcer: pathogenicity in the inflammatory-proliferative phase, chronicity, and treatment strategies. Front Endocrinol. 2025; 16: 1-28. https://doi.org/10.3389/fendo.2025.1657928.

[176] Jiang P, Li Q, Luo Y, Luo F, Che Q, Lu Z, et al. Current status and progress in research on dressing management for diabetic foot ulcer. Front Endocrinol (Lausanne). 2023; 14: 1221705. https://doi.org/10.3389/fendo.2023.1221705.